2022 annual financial data
China SXT Pharmaceuticals 2022 Financial results
Direct answer
Revenue was 2,602,281 USD.
Operating income was -5,189,673 USD and net income was -5,736,095 USD.
Operating cash flow was -2,374,531 USD.
Get free China SXT Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,602,281 USD
- Operating income
- -5,189,673 USD
- Net income
- -5,736,095 USD
- Operating cash flow
- -2,374,531 USD
Explore related company data
View all 2022 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Net marginView Operating cash flow marginView all China SXT Pharmaceuticals financial years